



HAL
open science

Evaluation of a rapid diagnostic assay for detection of SARS CoV-2 antigen in nasopharyngeal swab

Sidonie Lambert-Niclot, Alexis Cuffel, Samuel Le Pape, Christelle Vauloup-Fellous, Laurence Morand-Joubert, Anne-Marie Roque-Afonso, Jérôme Le Goff, Constance Delaugerre

► To cite this version:

Sidonie Lambert-Niclot, Alexis Cuffel, Samuel Le Pape, Christelle Vauloup-Fellous, Laurence Morand-Joubert, et al.. Evaluation of a rapid diagnostic assay for detection of SARS CoV-2 antigen in nasopharyngeal swab. *Journal of Clinical Microbiology*, 2020, 10.1128/JCM.00977-20 . hal-02613787

HAL Id: hal-02613787

<https://hal.sorbonne-universite.fr/hal-02613787>

Submitted on 20 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Evaluation of a rapid diagnostic assay for detection of SARS CoV-2 antigen in**
2 **nasopharyngeal swab**

3
4 Sidonie Lambert-Niclot ^{1,2}, Alexis Cuffel ³, Samuel Le Pape ⁴, Christelle Vauloup-Fellous ⁴, Laurence
5 Morand-Joubert ^{1,2}, Anne-Marie Roque-Afonso ⁴, Jérôme Le Goff ^{3,5}, Constance Delaugerre ^{3,6}, on
6 behalf of the AP-HP/Universities/Inserm COVID-19 research collaboration

7

8 ¹*INSERM-Sorbonne Universités UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis*
9 *d'Epidémiologie et de Santé Publique (iPLESP)*

10 ²*Hôpital Saint-Antoine, Laboratoire de virologie, Paris, France,*

11 ³*Hôpital Saint Louis, Laboratoire de virologie, Paris, France*

12 ⁴*Service de Virologie, Hôpital Paul-Brousse, Inserm U 1193 ; Université Paris-Saclay*
13 *Villejuif, APHP Paris-Saclay, France*

14 ⁵*Université de Paris, Inserm U976, Team Insight, F-75010 Paris, France*

15 ⁶*INSERM U944, Université de Paris, France*

16

17 Corresponding author: Sidonie Lambert-Niclot, sidonie.lambert@aphp.fr.

18

19 Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the virus causing causing Coronavirus
20 disease 2019 (COVID-19) was reported for the first time in Wuhan (Hubei, China) in December 2019
21 (1, 2) and has become a major public health concern all over the world. Early diagnosis is crucial for
22 patient management and outbreak control. Most tests currently used for detection of SARS-CoV-2 rely
23 on viral RNA amplification by using RT-PCR and require a few hours before results release. Hence,
24 highly sensitive immunological diagnostic methods that directly detect viral antigens in clinical samples
25 would be very helpful for rapid and accurate diagnosis of COVID-19.

26 Here, we evaluated a rapid diagnostic test, COVID-19 Ag Respi-Strip CORIS (BioConcept®, Gembloux,
27 Belgium), for detection of the SARS-CoV-2 antigen in nasopharyngeal secretions. The assay is ready to
28 use and based on a nitrocellulose membrane technology with colloidal gold nanoparticles sensitized
29 with monoclonal antibodies directed against highly conserved SARS-CoV-2 nucleoprotein antigens. We
30 compared this test with RT-PCR, the current reference assay in virology laboratories of three university

[Texte]

31 hospital groups from Assistance-Publique-Hôpitaux de Paris (APHP), (Saint-Antoine-Tenon-Trousseau,
32 Saint-Louis-Lariboisière and Kremlin Bicêtre-Paul Brousse). Different RT-PCR methods were used
33 (RealStar Altona®, Anatolia®, Cobas 6800 Roche®, Allplex™ 2019-nCoV Assay Seegene®). All assays
34 amplify SARSCoV2 E gene. Cycle threshold (Ct) values were recorded. Nasopharyngeal samples were
35 tested prospectively within a few hours after collection and without any cooling or freezing step, from
36 April 1st to April 15th 2020. Swabs were collected in various transport media (COPAN UTM 3ml, Virocult
37 1 ml, Eswab Amies 1 ml, 4MRT 3 ml, 0.9% NaCl buffer and COBAS ROCHE). The first four samples
38 collected in COBAS medium tested gave invalid results. We therefore excluded such samples from the
39 study. Analysis included 138 nasopharyngeal samples of which 94 (68.8%) were positive for SARS-CoV-
40 2 by RT-PCR. Compared to RT-PCR, the specificity of the test was 100% (CI 95%: 91.8-100). Among the
41 94 RT-PCR positive samples, the rapid test only detected 47 specimens, resulting in a sensitivity of
42 50.0% (95 CI: 39.5-60.5). In nine positive and eight negative tests, control lines were barely visible.
43 Median of E gene Ct values differed significantly between positives (median =21, Interquartile range
44 (IQR) [17.0-23.0]) and negatives (28.3, IQR:[25.6-33.0]) antigenic test results ($p<0.0001$) (Figure 1). A
45 study conducted by the manufacturer mentioned a sensitivity of 76.7% for samples positive with a Ct
46 value under 25 (3). In our study, the test would have a sensitivity of 82.2 % for Ct values under 25.
47 In our study, the COVID-19 Ag Respi-Strip CORIS® had a sensitivity of 50% compare to RT-PCR. The test
48 was more sensitive for high viral loads and could perhaps be used for patients within a few days after
49 symptoms onset when the load in upper respiratory tract is at its peak. Considering current low COVID
50 19's prevalence of 0.19 % in France, prospective studies should be conducted to determine the best
51 settings for its implementation.

52

53

54

55

56 **References**

[Texte]

57

58 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei
59 Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J,
60 Cao B. 2020. Clinical features of patients infected with 2019 novel coronavirus in
61 Wuhan, China. *Lancet* 395:497–506.

62 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma
63 X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research
64 Team. 2020. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*
65 382:727–33.

66 3. Mertens P, De Voe N, Martiny D, Jassoy C, Mirazimi A, Cuypers L, Van den Wijngaert S, Monteil
67 V, Melin P, Stoffels K, Yin N, Mileto D, Delaunoy S, Magein H, Lagrou K, Bouzet J, Serrano G, Wautier
68 M, Leclipteux T, Van Ranst M, Vandenberg O, and LHUB-ULB SARS-CoV-2 working diagnostic group.
69 Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic
70 Context. 2020 *Frontiers in medicine*
71 https://www.frontiersin.org/articles/10.3389/fmed.2020.00225/full?utm_source=Email_to_author
72 [s_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field](https://www.frontiersin.org/articles/10.3389/fmed.2020.00225/full?utm_source=Email_to_author&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Medicine&id=551560)
73 [=&journalName=Frontiers_in_Medicine&id=551560](https://www.frontiersin.org/articles/10.3389/fmed.2020.00225/full?utm_source=Email_to_author&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Medicine&id=551560)

74

75

76 **Figure 1.** COVID-19 Ag Respi-Strip CORIS results according to real-time PCR Ct values. All cycle
77 threshold values of E gene real-time PCR positive assays are shown for positive and negative COVID-
78 19 Ag Respi-Strip CORIS assay results. Results gathering Ct values for all real-time PCR positive assays
79 are depicted by squares. Ct values between samples positive or negative for the antigenic assay are
80 significantly different (* indicates a p-value < 0.0001). Ct values corresponding to the Cobas 6800,
81 Allplex, Anatolia, and RealStar assays are depicted by triangles, diamonds, circles and reversed
82 triangles respectively.

83

84

85

[Texte]

